Bringing Evidence into Practice: Psoriasis Management in the Age of Newer Biologics

Activity Details
  • Credit Amounts:
    • CME: 1.25
    • Other: 1.25
  • Cost: Free
  • Release: Apr 20, 2017
  • Expires: Apr 21, 2018
  • Estimated Time to Complete:
    1 Hour(s)  15 Minutes
  • System Requirements:
  • Average User Rating:
    (2 Ratings)

Faculty

Gary Goldenberg Gary Goldenberg, MD
Assistant Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai Hospital
New York, New York

Linda Stein Gold Linda Stein Gold, MD
Director of Clinical Research
Department of Dermatology
Henry Ford Hospital
Detroit, Michigan

Needs Statement

Plaque psoriasis is an autoimmune disorder that affects about 7.5 million people in the United States. [AAD 2015]. Treatment of plaque psoriasis depends on the severity and location of disease, as well as shared-decision making with the patient.

The dermatologist is the primary provider for patients with plaque psoriasis. Many primary care practitioners (PCPs) also manage patients with psoriasis, although at a much lower frequency. 

Given the great burden of the disease and associated comorbidities, it is critical that clinicians who care for patients with psoriasis are knowledgeable about the latest understanding of the pathophysiology of the disease, as well as the nuances of current and emerging agents for moderate, and severe plaque psoriasis—from mechanism of action of each of the agents, to efficacy and safety data, to appropriate dosing.

Target Audience

This activity has been designed to address the educational needs of physicians specializing in dermatology. It will also benefit dermatology nurse practitioners, and PAs, as well as primary care clinicians (internal medicine and family practice) who manage patients with psoriasis.

Objectives

Upon completion of this educational activity, participants will be able to:

  • Review the clinical guideline recommendations for earlier, aggressive treatment of moderate to severe plaque psoriasis as a systemic disease with systemic agents and/or biologic drugs.
  • Explain newer pathways for the development of plaque psoriasis and their implications for determining treatment, based on current evidence.
  • Summarize the most current evidence for newer therapies, which will guide patient selection, treatment goals, and response monitoring in patients with psoriasis.

Accreditation

CME
The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

ACGME Competencies - Patient care, Medical knowledge, and Practice-based learning and improvement

PA Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 credits for completing this activity.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.  Individuals are responsible for checking with the AANPCP for further guidelines.

Other
UK Healthcare CECentral certifies this activity for 1.25 hours of participation.

Faculty Disclosure

Gary Goldenberg, MD, (Speaker) has relevant financial relationships with commercial interests as follows:
Retained Consultant: AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, and Valeant Pharmaceuticals International, Inc.
Speakers Bureau: AbbVie Inc., Celgene Corporation, Eli Lilly and Company, and Novartis Pharmaceuticals Corporation
Honoraria: Valeant Pharmaceuticals International, Inc

Linda Stein Gold, MD, (Speaker) has relevant financial relationships with commercial interests as follows:
Grant/Research Support: Celgene Corporation; LEO Pharma Inc.; Pfizer Inc.
Retained Consultant: Celgene Corporation; LEO Pharma Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Promius Pharma, LLC.; Taro Pharmaceutical Industries Ltd.
Speakers Bureau: Celgene Corporation; LEO Pharma Inc.; Novartis Pharmaceuticals Corporation;  Taro Pharmaceutical Industries Ltd.

No planners or content reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgment

This activity is provided by University of Kentucky College of Medicine. Paradigm Medical Communications, LLC is the educational partner.

This activity is supported by an unrestricted educational grant from Novartis Pharmaceuticals Corporation.

Instructions For Participation

To receive a CME certificate of participation, you should:

  • Follow instructions to register or log in with your professional information and complete the pre-activity assessment.
  • View the online activity in its entirety.
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest.

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation and it will be stored in your online transcript.